$8.00Purchase & earn 8 points
no large-scale controlled trials Lack of FDA approval process No sponsor has pursued formal approval Quality concerns Peptide impurities and characterization challenges in unregulated manufacturing The economic reality: Unpatentable peptides cant justify the $50100M+ investment required for Phase 3 clinical trials, which is why BPC-157 has peer-reviewed preclinical data but no completed human trials
Change history 16 November 2011 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication References Adams TE, Epa VC, Garrett TP, Ward CW (2000) Structure and function of the type 1 insulin-like growth factor receptor
B Vitamins and the Brain: Mechanisms, Dose and Efficacy--A Review
This study used a V CRESC Cp10 product available in Japan, which contained collagen peptides (10 g) and a variety of vitamins and minerals in a 125-mL oral supplement that patients were able to consume during the treatment and within 5 months of being hospitalized